Product Summary
The study is given to the analysis of the latest growth trends and prospects for the Actinic Keratosis market.
The section „Actinic Keratosis Market“ includes an examination of the situation in major sections of the Actinic Keratosis market. The markets in European Union countries are examined in more detail, giving a timeline of financial results reported by major 3PL providers in 2017.
Browse full report: https://www.credenceresearch.com/report/actinic-keratosis-market
Market Insight:
Actinic keratosis (AK) is characterized by skin papules, macules or plaques resulting from prolonged exposure to harmful UV exposure and can result in squamous cell carcinoma. Risk of developing actinic keratosis increases with advancing age and is particularly higher in men as against women. About 5-20% of patients with actinic keratosis lesions develop malignant and potentially fatal squamous cell carcinomas.
Among the various treatment methods available, destructive therapies such as liquid nitrogen cryotherapy and surgical therapy constitute the gold standard for AK treatment. In 2015, cryotherapy was the most commonly sought treatment by clinicians. However, better clinical results of photodynamic therapy and growing preference for treatments based on drug-device combination have urged both caregivers and patients to opt for novel treatment methods that offer both advanced efficacy, aesthetic benefits and reduced risk of future malignancies. Topical treatment is a prolonged treatment and comparatively more effective than other treatments but patient compliance is the key issue that hinders the growth of this segment. Photodynamic therapy is the fastest growing treatment throughout the forecast period due to rising demand for non-invasive surgeries, and less treatment sessions are the key factors expected to assist this market
North America is the largest market for actinic keratosis treatment due to growing prevalence of AK, better public awareness about occurrence of AK and associated risk of squamous cell carcinoma. According to American Academy of Dermatology (AAD), approximately 60% of the Americans aged 40 year or above, Actinic Keratosis is predisposed to develop having at least 1 AK lesion. Actinic keratosis is precursors of squamous cell cancer. U.S. held the largest share in the actinic keratosis market in 2015 owing to current prevalence of actinic keratosis in the region.Asia Pacific is the fastest growing market for AK treatments. Australia has the highest prevalence of actinic keratosis ranging between 40% to 60% in adult population. Growing awareness in the region and rapid development in healthcare infrastructure and healthcare expenditure are the key growth factors in Asia Pacific actinic keratosis market.
This market is majorly driven by wide presence of generic drugs and is moderately competitive. Photodynamic therapy market has developed a niche with methyl aminolevulinate and aminolevulinic acid drugs. Galderma and DUSA pharmaceuticals are the chief players in this space. Some of the major players in the global actinic keratosis market are Tolmar Pharmaceuticals, Inc, DUSA Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Aqua Pharmaceuticals, LLC, Galderma SA, Perrigo Company plc, LEO Laboratories, Apotex and others.
“Actinic Keratosis Market” is a new report by us that explains how companies‘ acquisition expenditures, media spend, business strategies, marketing and sales strategies and practices, and business plan are set to change in 2017-2018. This paper gives you access to the category-level spending forecasts, business challenges, budgets, supplier selection criteria, the current size of the marketing and promotion budgets and investment opportunities for senior-level officials. The report also identifies the expected growth of buyers and suppliers, capital expenditure, staff hiring, M and A, and e-procurement. This report not only gives access to the views and strategies of business decision makers and rivals but also examines their actions circling business priorities. The report also provides access to information categorized by company type and sizes, region,
Introduction and Landscape
Why was the report written?
This report is the result of an extensive survey drawn from Our Research’s elite panel of leading global senior level executives from enterprises such as such as medical devices, mining, packaging, power, oil, and gas, food and beverage, airports and pharmaceutical. The report covers key topics such as appropriation behaviors and strategies, the current size of the marketing and advertising budgets. Besides the report also recognizes the threats and possibilities, economic outlook trends, media channel spending outlooks, M and A expectations, marketing agency selection models, media budgets, business challenges and confidence among senior-level executives across various industries. Most secondary research papers are based on general industry drivers and do not understand the industry officials‘ attitude and changing behaviors, creating a gap in showing the business opportunity of the industry. In an effort to bridge this gap, Our Research created this primary-research based report by selecting the opinions of various stakeholders in the value-chain of the industry
This report offers:
- Analysis of several products, and regions that would provide the clear understanding of the ongoing and future trends in the global Actinic Keratosis market
- Assessment of market dynamics such as drivers, restraints, and opportunities prevalent in the market
- Quantitative assessment of the current market size and future estimations for the period from 2016 to 2026, along with CAGRs for the period from 2018 to 2026
- Company profiles that will highlight key information about the imperative players operating in the global Actinic Keratosis devices market
Company Profiles
6.1 Tolmar Pharmaceuticals, Inc.
6.1.1 Tolmar Pharmaceuticals, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.2 DUSA Pharmaceuticals, Inc. (Sun Pharma)
6.2.1 DUSA Pharmaceuticals, Inc. (Sun Pharma): Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.3 Valeant Pharmaceuticals International, Inc.
6.3.1 Valeant Pharmaceuticals International, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.4 Aqua Pharmaceuticals, LLC
6.4.1 Aqua Pharmaceuticals, LLC: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.5 Galderma S.A.
6.5.1 Galderma S.A.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.6 Perrigo Company plc,
6.6.1 Perrigo Company plc,: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.7 Apotex, Inc.
6.7.1 Apotex, Inc.: Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
6.8 LEO Laboratories Ltd. (LEO Pharma A/S)
6.8.1 LEO Laboratories Ltd. (LEO Pharma A/S): Company Snapshot (Business Description; Financial Health and Budget Allocation; Product Position/Portfolio; News Coverage)
Here you can get an updated sample on this report: https://www.credenceresearch.com/sample-request/58011
About us:
Credence Research is a worldwide market research and counseling firm that serves driving organizations, governments, non-legislative associations, and not-for-benefits. We offer our customers some assistance with making enduring enhancements to their execution and understand their most imperative objectives. Over almost a century, we’ve manufactured a firm extraordinarily prepared to this task.
Who we are
Credence Research is a worldwide firm, containing more than 15 research consultants and almost 100 research and information professionals.
Our customers mirror our worldwide nature. Around 45% are in Europe, 30% in the Americas, 13% in the Asia Pacific and 12% in the Middle East and Africa.
Our firm is intended to work as one. We are a solitary global research organization united by a solid arrangement of qualities, concentrated on customer effect.
Contact Us:
Credence Research Inc.
105 N 1st ST #429
SAN JOSE
CA 95103
United States
Email: